Monsanto Gains Market Share and 4 Stock Analyses to Follow

Energizer Holdings Inc. (NYSE:ENR) growth is believed by RBC Capital believes that Energizer’s growth to begin accelerating during 2Q13, and the firm is convinced that the company’s annual EPS growth may potentially rise to 10 percent over the next few years. The firm keeps its Outperform rating on the stock.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has been named one of Piper Jaffray’s top picks for 2013 due to the company’s promising Hepatitis C virus pipeline. Piper thinks that data readouts during 2013 ¬†should put Achillion in the position to be a potential take out candidate. The firm keeps its Overweight rating on the stock.

Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.

Monsanto Co. (NYSE:MON): According to Piper Jaffray, its seed dealer checks have shown that Monsanto has begun to gain market share in corn with a favorable mix shift toward higher priced offerings. Piper believes that Monsanto’s Q1 results will probably be a positive surprise and that management will probably keep its mid-teens earnings growth guidance. The firm reiterates its Overweight rating and a $116 price target on the stock.

Cardiovascular Systems Inc. (NASDAQ:CSII): After the firm surveyed cardiologists, JMP Securities thinks that coronary atherectomy, provided by Cardiovascular Systems, reflects a $700 million market opportunity. The firm believes that the company has begun to gain momentum and it could potentially become a more viable takeover target. The firm keeps its Outperform rating on the stock.

Cytokinetics Inc. (NASDAQ:CYTK): After the firm attended Cytokinetics’ R&D day, JMP Securities thinks that that the company possesses multiple value-inflecting and potentially transformative catalysts in 2013. The firm predicts that the company will obtain a partner for its tirasemtiv treatment, and it keeps its Outperform rating on the stock.

Investing Insights: Can Molycorp Outperform With a New CEO?